Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
Open Access
- 14 September 2021
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 38 (10) , 5345-5360
Abstract
Introduction This integrated phase 3 analysis examined efficacy and cardiovascular safety for roxadustat vs erythropoiesis-stimulating agents (ESAs) in dialysis-dependent patients. Methods Efficacy and safety results from four phase 3, randomized, open-label studies comparing roxadustat to ESAs (PYRENEES, SIERRAS, HIMALAYAS, ROCKIES) in dialysis-dependent patients with anemia of chronic kidney disease (CKD) were evaluated by study, pooled population and in two subgroups: incident dialysis and stable dialysis. The primary efficacy endpoint per study was hemoglobin change from baseline (CFB) to weeks 28–36 using least-squares mean difference (LSMD) without rescue therapy. Pooled safety endpoints included time to major adverse cardiovascular event (MACE; myocardial infarction, stroke, and all-cause mortality [ACM]) and MACE+ (MACE plus congestive heart failure or unstable angina requiring hospitalization), ACM, and treatment-emergent adverse events (TEAEs). MACE and MACE+ were evaluated for non-inferiority at 1.8 and 1.3 margins using hazard ratios (HRs) and 95% confidence intervals (CIs). TEAEs were descriptively summarized. Results In total, 4714 patients were randomized (2354 roxadustat; 2360 ESA). Hemoglobin CFB to weeks 28–36 achieved non-inferiority for roxadustat vs ESA in each study. Roxadustat was non-inferior to ESA for risks for MACE and MACE+ in the entire cohort (MACE: HR 1.09, 95% CI 0.95–1.26; MACE+ : HR 0.98, 95% CI 0.86–1.11) and similar to the incident dialysis and stable dialysis subgroups; ACM results were consistent with MACE and MACE+ (HR 1.13, 95% CI 0.95–1.34). TEAEs were generally comparable between groups. Conclusion Roxadustat improved hemoglobin similarly to ESA while demonstrating comparable cardiovascular and overall safety profiles in a wide spectrum of dialysis-dependent patients with anemia of CKD. Roxadustat represents an oral alternative to ESAs for achieving a target hemoglobin for anemia of CKD in dialysis-dependent patients.Keywords
This publication has 36 references indexed in Scilit:
- Peginesatide in Patients with Anemia Undergoing HemodialysisNew England Journal of Medicine, 2013
- The New FDA Labeling for ESA—Implications for Patients and ProvidersClinical Journal of the American Society of Nephrology, 2012
- Development of a Database of Health Insurance Claims: Standardization of Disease Classifications and Anonymous Record LinkageJournal of Epidemiology, 2010
- Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomesKidney International, 2008
- Greater Epoetin alfa Responsiveness Is Associated With Improved Survival in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Erythropoiesis‐stimulating agent hyporesponsiveness (Review Article)Nephrology, 2007
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohortKidney International, 2006
- Epoetin requirements predict mortality in hemodialysis patientsAmerican Journal of Kidney Diseases, 2004
- Anemia as a risk factor for cardiovascular diseaseKidney International, 2003